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Many diseases are characterized by altered expression of proteins
or peptide antigens which define diagnosis or disease behaviour.
The biological significance of an antigen is generally dependent
on its concentration and there is a need for a means of measuring
antigen concentration in tissue sections. Visualization of tissue
morphology is important because antigen expression is commonly
related to a particular cell population within a mixed tissue.
Immunohistochemistry (IHC) retains tissue morphology but
does not reliably quantitate antigen while assays of extracts of
homogenized tissue involve destruction of morphology.
The principal aim of this work was, first, to establish and vali-
date a method for quantifying protein concentration in histological
sections of colorectal cancer and then, second, to apply this
technique to a clinically relevant situation.
Radioimmunoluminography (RILG), a generally applicable
method for measurement of antigen concentration in tissue
sections, is based on quantification of radiolabelled antibody
binding to tissue sections using a phosphor plate imager. The
amount of antibody bound in a given area of the section will be
proportional to the amount of antigen present if saturating concen-
trations of antibody are used. The distribution of radioactivity in a
section is mapped by a phosphor plate imager which quantitates
antigen-bound antibody pixel by pixel in the digital image. The
high sensitivity and linear response over five orders of magnitude
of this instrument (Chung et al, 1994; Okuyama et al, 1994) make
it practical to quantitate the very small amounts of radioactivity
present. The pixel size of available phosphor imagers (25–90 mm)
gives sufficient resolution for correlation with light microscope
images. Here we show that the concentration of carcinoembryonic
antigen (CEA) in histological sections can be quantitated using a
calibration line constructed from RILG binding to known amounts
of CEA. The accuracy of RILG has been established by assessing
CEA levels in sections of human colon carcinoma xenografts.
In antibody-directed targeted therapy of cancer the localization
of anti-tumour antibodies in tumours varies greatly between indi-
vidual patients and as yet the factors responsible for this variation
have not been critically defined (Boxer et al, 1992). Whilst there
have been a number of papers implicating a variety of putative
cellular and physiological factors (Jain, 1989; Poznansky and
Juliano, 1984; Shockley et al, 1991) there has been surprisingly
little attention paid to the importance of tumour antigen concentra-
tion. The ability of RILG to directly measure CEA concentration
in biopsies is shown to be clinically useful and can enable us to
predict the likely efficiency of antibody-targeted therapy of
colorectal carcinoma.
MATERIALS AND METHODS
Tissue preparation
Human adenocarcinoma xenografts (Pedley et al, 1996) with
different levels of CEA expression, SW116, LS174T(1),
LS174T(2), HT29/219 (colon), OVCA (ovarian), PAPA (breast)
and a CEA-negative, rat mammary (RM) tumour, were used to
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establish the technique. Fresh samples of tumour xenograft were
snap-frozen in iso-pentane (cooled in liquid nitrogen) and 6-mm
cryostat sections were prepared. For the clinical study sections
were cut from colorectal carcinomas resected from patients
receiving radioimmunoguided surgery (Blair et al, 1990). Tumour
from 15 patients was assayed for the cryostat study (6-mm
sections) and from 19 patients for the paraffin study (3-mm
sections). All sections were mounted on slides coated with 2% 3-
aminopropyltriethoxysilane (Sigma-Aldrich Ltd, U.K.) in acetone.
Antibodies
A5B7 anti-CEA (Harwood et al, 1986) and A161 (Hitchens et al,
1989) anti-alphafetoprotein antibodies were labelled (Fraker and
Speck, 1978) with 125I (21.5–120.5 MBq mg21 and 104 MBq mg21
respectively) passed through a 0.22 mm filter (Gellman Ltd,
Northampton, UK). Percentage incorporation of 125I into antibody
was calculated, from thin layer chromatographs (TLC) on 0.25-
mm silica gel (Macherey-Nagel, Polytron sil G/UV 254), using
phosphor image plate technology (see later).
Radioimmunoassay
A total of 0.2–1.0 g of each tumour xenograft was homogenized in
5 ml of buffer with protease inhibitors; 4-(2-aminoethyl)-benzene-
sulphonyl fluoride hydrochloride (ICN, UK); pepstatin A and
leupeptin (Sigma, Poole, UK) and incubated for 2 h at 378C in
phosphatidyl-inositol-specific phospholipase C (Sigma, UK)
(2.95 units g21 wet weight). After mixing, by vortexing, tubes
were incubated for 2 h at 378C in a shaking incubator (New
Brunswick Scientific Ltd, UK) at 200 oscillations min21. The
preparation was centrifuged for 30 min at 14 300 g at 48C in a high
speed centrifuge (Beckman JA20.1; Beckman Ltd, UK) to remove
all the cell debris. Supernatant was removed and stored at 48C and
the pellet was resuspended in 5 ml of extraction buffer, mixed
thoroughly by vortexing and centrifuged for a further 30 min at
high speed (14 300 g). The supernatant was removed and stored at
2 708C. Samples were assayed for CEA using the solid phase two-
site (ELSA-2) radioimmunoassay (RIA) kit (CIS International UK
Ltd) at neat, 1/10, 1/100 and 1/1000 dilutions. Each tube was
counted using a gamma counter (WIZARD; Pharmacia, UK).
Values for CEA for each tumour were expressed in ng g21 of wet
weight of tissue calculated with reference to a CEA standard line
produced using CEA standards from the commercial RIA kit.
Nitrocellulose dot blot assay
A total of 0.45-mm nitrocellulose Trans-blot membrane (Biorad
UK Ltd) was dotted with 10-ml aliquots of 0.05–5 mg g21 CEA and
allowed to air-dry for 30 min. The nitrocellulose was cut into
squares containing individual dots of antigen and assays
performed using 12-well plastic plates (Costar Ltd, UK). After
blocking with 5% bovine serum albumin in Tris–HCl buffered
saline pH 7.6 containing 1% normal horse serum for 1 h, 650 ml of
125I-labelled A5B7 anti-CEA antibody (75 mg g21) was added to
each well containing a nitrocellulose dot and incubated for 75 min
at room temperature (RT). After washing in five changes of
phosphate-buffered saline (PBS)–Tween (0.05%) nitrocellulose
Figure 1 Images of formalin-fixed paraffin sections of a tumour (T), a human colorectal adenocarcinoma and adjacent non-neoplastic mucosa (N), (A) stained
by haematoxylin and eosin, (B), (C) reacted for CEA by IHC and RILG respectively. CEA is shown by a brown reaction product with IHC and by scales of grey
with RILG. Unlike IHC, the RILG data is digital and also gives a qualitative assessment of CEA distribution
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squares were air-dried and exposed overnight to a phosphor
storage plate before scanning (400-A; Molecular Dynamics, UK).
Immunohistochemistry
Immunohistochemistry (IHC) was carried out as described previ-
ously (Southall et al, 1990) using an avidin–biotin–peroxidase
technique. Briefly, 5-mm cryostat sections of xenograft tumours
were air-dried, fixed in acetone and reacted with biotinylated
A5B7 anti-CEA antibody (Marshall et al, 1995) at 20 mg ml21 and
visualized using avidin–biotin–peroxidase complexes (Vector
Laboratories, UK). Under bright-field microscopy immunohisto-
chemically reacted sections were analysed and measurement of
CEA content was estimated by screening 20 randomly selected
high power fields (magnification 3 200) per xenograft tumour and
calculating the mean % CEA-reactive cells. For both the cryostat
and paraffin sections from cases of human tumour, following the
RILG assay, CEA antigen distribution was demonstrated, by incu-
bation with biotinylated horse anti-mouse immunoglobulins and
avidin–biotin–peroxidase complexes sequentially. Endogenous
peroxidase was blocked using a solution of 0.3% hydrogen
peroxide (Merck Ltd, UK) in methanol (Merck Ltd, UK).
RILG
Cryostat sections were fixed in 0.25% glutaraldehyde (40 min).
Cryostat and dewaxed paraffin sections were blocked in 5%
bovine serum albumin (BSA) in Tris–HCl buffered saline, pH 7.6
containing 1% normal horse serum. Binding of 125I-labelled A5B7
antibody (0.01–120 mg ml21 and subsequently 4.7–190 mg ml21) to
cryostat sections of xenografted tumours (CEA concentration
range 0.5–935 ng g21 as determined by RIA) was measured using
phosphor image analysis. RM tumour and A161 anti-AFP anti-
body were included as negative controls. Experiments were
performed in triplicate on three separate days to determine the
inter-assay variation. Antibody binding to sections of the
xenografts plateaued at approximately 60–75 mg ml21 (see Results
and Figure 3) and 75 mg ml21 was chosen as saturating concentra-
tion of antibody for subsequent work. Slides were incubated with
125I antibody for 1 h at RT, washed in five changes of Tris–HCl
buffer and air-dried. Slides were exposed to phosphor storage
plates for 1 h before scanning.
Quantitation of RILG
Binding of radiolabelled antibody to tumours was measured by
demarcating regions of interest. Regions were drawn using auto-
mated image analysis techniques (ImageQuant NT software for
Windows). Average counts per pixel were taken for the region and
a mean from triplicate sections used to generate antibody binding
curves. RILG values for xenografts and for all regions identified as
tumour from patients’ studies were recorded as average counts per
pixel and converted to ng g21 of CEA using the relevant part of the
CEA standard calibration line (0–1000 ng g21). Statistical analyses
were performed using a non-parametric test (Spearman rank corre-
lation test).
RESULTS
RILG images
Anti-CEA antibody binding to CEA by RILG in a section of colon
carcinoma is shown in Figure 1C. The number of counts in each
pixel of the image is directly related to the amount of 125I antibody
bound to CEA. IHC (Figure 1B) and haematoxylin and eosin
(Figure 1A) stained sections of the same tumour are shown for
comparison. RILG has the advantage of illustrating the hetero-
geneity of CEA expression within tumours, something which is
not demonstrable by traditional IHC methods. The range of counts
per pixel measured within a tumour region is evidence of hetero-
geneity of protein expression within the tumour mass. This is also
evident on visual inspection of RILG images (Figure 1C).
0 1000 2000 3000 4000 5000
CEA concentration (ng g–1)
A
v
e
r
a
g
e
 
c
o
u
n
t
s
 
p
e
r
 
p
i
x
e
l
2000
0
4000
6000
8000
y =–104.61 + 1.5419x  R^2=0.999
Figure 2 Binding of 125I anti-CEA antibody by RILG to known
concentrations of CEA, in a nitrocellulose dot blot assay
Figure 3 Binding of 125I anti-CEA antibody (concentration range 4.7–
190 mg ml21) by RILG to three CEA-expressing xenografts (LS174T(1),
OVCA and PAPA) and non CEA-expressing rat mammary carcinoma
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Quantitative analysis
The relationship of antibody binding to antigen was shown by
RILG to give a linear correlation (r 5 0.999) between 125I anti-
CEA and concentrations of CEA ranging from 0.05–5 mg g21 in
the nitrocellulose dot blots (Figure 2). Figure 3 shows the binding
curves for three of the xenograft tumours (LS174T (1), OVCA and
PAPA) and the control rat mammary carcinoma with increasing
concentration of 125I-antibody. After an initial rise in counts per
pixel with concentration, a plateauing effect is observed at
approximately 60–75 mg ml21. These data come from experiments
repeated on three successive days and the standard deviation for
each concentration is shown. Binding to non-CEAexpressing rat
mammary tumour was consistently very low and always below
that observed for even the lowest CEA-expressing tumours as
demonstrated in Figure 3. Tumour CEA concentrations measured
by RIA of tissue extracts from carcinoma xenografts were
compared with assessments of tumour CEA by % positive cells
using IHC and mean counts per pixel on RILG. Results shown in
Figure 4 demonstrate that IHC and RILG were each able to iden-
tify the low CEA-expressing (SW116) and high CEA-expressing
(HT29/219) tumours, but whilst RILG could accurately show the
intermediate level of CEA production IHC was unable to discrim-
inate between intermediate and high levels of expression. The
linear relationship of antibody binding to antigen in xenografts is
demonstrated by the regression line for the RILG data (r 5 0.994)
compared to that for IHC (r 5 0.47). Control RILG assays incu-
bating sections of xenografts with A161 anti-AFP antibody, and
rat mammary tumour with A5B7 anti-CEA antibody, always gave
results (data not shown) below that of the lowest CEA expressing
tumour (SW116). The CEA concentration of each xenograft calcu-
lated by RILG (78–578 ng g21) was closely correlated (P 5 0.025)
to that calculated by RIA (0.5–935 ng g21).
Clinical application
CEA levels estimated by RILG of cryostat sections of colorectal
carcinomas in 15 patients (30 regions) ranged from 38.9 to
594 ng g21 and for formalin-fixed paraffin study of 19 patients (79
regions) between 22.5 and 212.5 ng g21. The correlation of RILG
with parameters relevant to clinical management was assessed
by comparing these values with levels of tumour localization of
intravenously administered anti-CEA antibody in patients with
colorectal cancer who received radiolabelled antibody for radio-
immunoguided surgery. For both the cryostat study (15 patients)
and paraffin study (19 patients), a significant statistical correlation
was demonstrated between the percentage of injected radioactivity
localizing in tumour (0.5–10.6% and 0.9–10.6%) and for CEA
content (P 5 0.04 and P 5 0.02 respectively). Figure 5 shows the
data for the paraffin study.
DISCUSSION
This paper establishes a technique that uniquely combines
measurement of concentration of cellular products with preserva-
tion of tissue morphology, allowing the heterogeneity of protein
expression to be examined quantitatively. Currently, quantitative
ways to measure tissue proteins by methods such as RIA after
extraction, are limited by their failure to preserve cellular struc-
ture. Conversely, cellular techniques that maintain tissue architec-
ture, such as IHC for the demonstration of antigen, are not
quantitative. In this study the tumour antigen CEA was used to
establish RILG for human colorectal tissues. Positive and negative
antibody and antigen controls confirmed the specificity of RILG.
IHC was shown to be non-quantitative for CEA in that it was
unable to distinguish high from intermediate levels of CEA
reflecting the non-linearity of the colourimetric amplification
system. By contrast, the phosphor imaging system employed in
RILG gives highly efficient energy capture (detection threshold
for 125I is 0.23 dpm mm2 h21) and is linear over five orders of
magnitude (Chung et al, 1994; Okuyama et al, 1994), so that direct
detection of radiolabelled antibody or other ligand is achieved
without an amplification step. Antigen concentration is then
directly related to the amount of radiolabelled antibody bound
when antigen is saturated. Sensitivity was easily sufficient for the
range of CEA concentrations studied here (0.49–935 ng g21), but
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Figure 4 Comparison of RILG and IHC in relation to CEA measured by
radioimmunoassay of tumour homogenates in xenografts with different
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the full limits of sensitivity have not been explored and will prob-
ably vary from one antigen to another.
Having established RILG in experimental models we then tested
its utility in a clinical setting. The range of RILG CEA concentra-
tions from the patients’ study in cryostat section was similar to the
range for the xenografts. RILG CEA concentrations for the
paraffin section study of patients were generally at a lower level
than those for the cryostat study. The lower level antibody binding
may be due to prolonged formalin fixation or to histological
processing, or be related to the lesser thickness of section (3 mm vs
6 mm).
Phosphor imaging technology can also be used to quantitate
fluorescence and it is reasonable to suppose that this could also be
used for measuring tissue antigen concentrations. The pixel size of
current phosphor imagers (25–90 mm) enables phosphor plate and
light microscope images to be correlated. Groups of cells and
tissues can be readily investigated, but the resolution is not suffi-
cient for single-cell studies. These characteristics are particularly
valuable when studying conditions with heterogeneous antigen
expression, as seen in neoplastic and inflammatory pathology, and
gives insights not available from antigen measurements on tissue
homogenates. The value of this is illustrated by showing that CEA
concentration in areas of viable tumour is one parameter which
predicts the amount of intravenously administered antibody which
localizes in tumour. IHC had previously failed to demonstrate this
(Boxer et al, 1992). Tumour responses are reported in patients
treated with 131I-antibody to CEA (Lane et al, 1994) and antibody-
directed enzyme prodrug therapy – ADEPT (Bagshawe et al,
1995). RILG of tumour biopsies is likely to assist in selecting
those patients likely to respond to these treatments. The variation
within the data in Figure 5 supports the hypothesis that there are a
number of other cellular and physiological parameters (Jain, 1989;
Poznansky & Juliano, 1984; Shockley et al, 1991) affecting anti-
body localization. One such putative factor is the vascular supply
of tumours and this could also be studied by RILG.
This methodology could be adapted for direct quantitation of a
wide range of tissue antigens, cell surface receptors, mRNA and
viral RNA/DNA in histological sections leading to improved
diagnosis of disease, rational selection of patients for appropriate
therapy and better predictions of prognosis. The next phase of
the Human Genome Project will concentrate on functional analysis
of genes by studying their expression as proteins. This should
lead to a deeper understanding of normal cell function and patho-
logical states. In this context, the ability of RILG to accurately
measure the concentrations of proteins at the same time as
retaining their positions in tissues will contribute to knowledge of
how cells function.
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